D.E. Shaw & Co
TXMD icon

D.E. Shaw & Co’s TherapeuticsMD TXMD Stock Holding History

D.E. Shaw & Co’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,917
Closed -$372K – 5947
2021
Q4 		$372K Buy
20,917
+17,574
+526% +$527K ﹤0.01% 4563
2021
Q3 		$124K Buy
+3,343
New +$148K ﹤0.01% 4682
2021
Q1 		– Sell
-16,912
Closed -$1.02M – 4501
2020
Q4 		$1.02M Buy
16,912
+15,227
+904% +$1.04M ﹤0.01% 3007
2020
Q3 		$133K Buy
1,685
+1,192
+242% +$95K ﹤0.01% 3676
2020
Q2 		$31K Buy
493
+152
+45% +$8.85K ﹤0.01% 3937
2020
Q1 		$18K Sell
341
-2,085
-86% -$207K ﹤0.01% 3857
2019
Q4 		$294K Sell
2,426
-5,145
-68% -$740K ﹤0.01% 3634
2019
Q3 		$1.37M Buy
+7,571
New +$1.07M ﹤0.01% 2636
2019
Q2 		– Sell
-7,806
Closed -$1.9M – 3884
2019
Q1 		$1.9M Buy
+7,806
New +$2.07M ﹤0.01% 2189
2018
Q4 		– Sell
-10,892
Closed -$3.57M – 3997
2018
Q3 		$3.57M Sell
10,892
-11,838
-52% -$3.63M ﹤0.01% 1792
2018
Q2 		$7.09M Sell
22,730
-4,619
-17% -$1.41M 0.01% 1304
2018
Q1 		$6.66M Sell
27,349
-2,604
-9% -$730K 0.01% 1234
2017
Q4 		$9.05M Buy
29,953
+15,767
+111% +$4.39M 0.01% 1091
2017
Q3 		$3.75M Buy
14,186
+5,834
+70% +$1.69M 0.01% 1588
2017
Q2 		$2.2M Buy
8,352
+7,305
+698% +$1.83M ﹤0.01% 1913
2017
Q1 		$377K Sell
1,047
-237
-18% -$73.3K ﹤0.01% 2867
2016
Q4 		$370K Sell
1,284
-15,707
-92% -$4.87M ﹤0.01% 3020
2016
Q3 		$5.79M Sell
16,991
-3,954
-19% -$1.44M 0.01% 1206
2016
Q2 		$8.9M Buy
20,945
+146
+0.7% +$60.2K 0.02% 954
2016
Q1 		$6.66M Buy
20,799
+4,068
+24% +$1.39M 0.01% 1095
2015
Q4 		$8.68M Buy
16,731
+13,649
+443% +$5.04M 0.01% 1038
2015
Q3 		$903K Buy
3,082
+318
+12% +$113K ﹤0.01% 2668
2015
Q2 		$1.09M Buy
2,764
+2,214
+403% +$781K ﹤0.01% 2649
2015
Q1 		$166K Buy
550
+20
+4% +$4.88K ﹤0.01% 3476
2014
Q4 		$118K Buy
+530
New +$109K ﹤0.01% 3887

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

D.E. Shaw & Co's TXMD Position: Q1 2022 in Review

D.E. Shaw & Co sold out of TherapeuticsMD (TXMD) in Q1 2022, closing a stake of 20,917 shares — an estimated $372K sold.

D.E. Shaw & Co first reported a position in TXMD in Q4 2014 and held it in 25 quarters. The position peaked at $9.05M in Q4 2017. 124 funds tracked by Wall St. Rank hold TXMD as of Q1 2022.

  • D.E. Shaw & Co reported no remaining TherapeuticsMD position as of Q1 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 20,917 TherapeuticsMD shares in Q1 2022, an estimated $372K.
  • D.E. Shaw & Co first reported a position in TherapeuticsMD in Q4 2014 and held it in 25 quarters.
  • D.E. Shaw & Co's TherapeuticsMD position peaked at $9.05M in Q4 2017.
  • 124 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.